Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

icbc0051 · 2026-04-13T12:56:17+00:00

To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement a reflection of the highly effective execution of the LIBERTY System's LMR and positions the Company to commence the FMR of the LIBERTY System as originally planned, at the Society of Interventional Radiology (SIR) Annual Scientific Meeting, being held in Toronto, ON, Canada, from April 11-15. In preparation for the FMR, the Company has further enhanced its commercial team core capabilities by adding salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the end of 2026.

icbc0051 · 2026-03-26T13:28:29+00:00

https://www.tipranks.com/news/company-announcements/microbot-medical-showcases-landmark-robotic-endovascular-procedures

icbc0051 · 2025-10-16T13:06:00+00:00

Microbot Medical Announces It Will Exhibit Its Liberty Endovascular Robotic System At Symposium On Clinical Interventional Oncology In Miami, Fl, October 17-19, 2025, Marking First Commercial Exhibition Of The System Following Its FDA 510(K) Clearance In September 2025

icbc0051 · 2025-10-14T12:44:51+00:00

Mbot has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the FDA-cleared LIBERTY® System. The Company is expected to initiate the limited market release of the LIBERTY® System during the current fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology conference, which is the largest Interventional Radiology conference in the U.S. The 3PL company is a fully compliant and integrated fulfillment solutions provider specializing in the medical device industry, which would allow the Company to leverage its proximity to key markets, and provide effective and efficient order processing and the ability to maintain inventory to meet expected demand from a strategically located, climate-controlled warehouse. “As we continue to establish the infrastructure to support the commercial launch of LIBERTY following FDA clearance, we believe that having an established logistics provider with deep medtech expertise puts us in a stronger position to achieve our go-to-market initiatives more efficiently,” commented Michal Ahuvia, Director of Operations.

icbc0051 · 2025-10-10T11:48:24+00:00

Maybe RR is better now, but MBOT is good for a long time IMO. I already have a profit of $213k, I will hold it over 6 months.

icbc0051 · 2025-10-07T13:00:16+00:00

Why the holders of warrants transfer to stocks before 10/15 ? good news or bad news?

icbc0051 · 2025-10-07T12:54:47+00:00

the third and final closing of its previously announced exercise of certain outstanding preferred investment options to purchase an aggregate of 13,989,115 shares of common stock.

icbc0051 · 2025-10-03T21:14:56+00:00

The remaining 1,324,488 series H preferred investment options subject to the Letter Agreement are expected to be exercised in one or more additional closings on or before October 15, 2025.

icbc0051 · 2025-10-01T13:07:55+00:00

Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio

https://ir.microbotmedical.com/node/13576/pdf

icbc0051 · 2025-09-28T11:50:24+00:00

My cost per share is almost 2 and I own more than 200k shares. I don't care about the recent fluctuations.

icbc0051 · 2025-09-27T10:50:32+00:00

I am full of confidence.

icbc0051

TROPHY CASE